Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

FDA Authorizes New Long-Acting Monoclonal Antibodies (AZD7442 or EVUSHELD) for Pre-Exposure Prevention of COVID-19 in Certain Individuals

In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are informational only, should never be considered medical advice, and should never be acted on without review with your health care team.

This is the great news we have been waiting for.

CLL Society worked hard to ensure that those “certain individuals” with access to this passive immunity were the most vulnerable, namely the immunocompromised, including those with CLL / SLL.

This has the potential to change everything and give us freedom like that already enjoyed by those vaccinated who have a normal immune system.

Here are the FDA’s official press release and the accompanying FAQ that go into more detail:

Here is the press release from AstraZeneca that includes a quote from our own Dr. Brian Koffman:

There is reason to believe the shots could be available very quickly, maybe even later this month. What a Christmas present that would be!

Stay tuned to for the latest news. More details to follow. As they say, this is a breaking story and there is much that we don’t yet know.

Stay strong, we are all in this together.

Brian Koffman MDCM (retired) MSEd (he, him, his)
Co-Founder, Executive VP and Chief Medical Officer
CLL Society, Inc.

CLL Society - COVID-19

When appropriate, the CLL Society will be posting updates and background information on the present Coronavirus pandemic focusing on reliable primary sources of information and avoiding most of the news that is not directly from reliable medical experts or government and world health agencies.